1-6 of 6
Eric Winquist
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Eric Winquist, Sebastien J. Hotte, Kim Chi, Srikala Sridhar, Susan Ellard, Michael Ong, Nayyer Iqbal, Muhammad Salim, Urban Emmenegger, Joel R. Gingerich, Aly-Khan Lalani, Pierre Major, Christian Kollmannsberger, Steven Yip, Aaron Hansen, Daygen Finch, Christina Canil, James Hutchenreuther, Francisco Vera-Badillo, Martin Smoragiewicz, Michael Cabanero, Ming-Sound Tsao, Elie Ritch, Alexander W. Wyatt, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 45–55.
https://doi.org/10.1158/1078-0432.CCR-24-1612
Published: 06 January 2025
View article titled, Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Neil E. Fleshner, Rashid K. Sayyid, Aaron R. Hansen, Joseph L.K. Chin, Ricardo Fernandes, Eric Winquist, Theodorus van der Kwast, Joan Sweet, Katherine Lajkosz, Miran Kenk, Karen Hersey, Rosette Veloso, Doron Berlin, Jaime O. Herrera-Caceres, Srikala Sridhar, Madeleine Moussa, Antonio Finelli, Robert J. Hamilton, Girish S. Kulkarni, Alexandre R. Zlotta, Anthony M. Joshua
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (19): 3867–3874.
https://doi.org/10.1158/1078-0432.CCR-23-0731
Published: 02 October 2023
View article titled, Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
Open the PDF for Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Abstract PR02: Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status

Farhad Ghasemi, Stephenie D. Prokopec, Danielle MacNeil, Neil Mundi, Christopher Howlett, William Stecho, Kevin Fung, John Yoo, Eric Winquist, Steven Gameiro, Axel Sahovaler, Paul Plantinga, Joe S. Mymryk, John W. Barrett, Paul C. Boutros, Anthony C. Nichols
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_2): PR02.
https://doi.org/10.1158/1557-3265.AACRAHNS19-PR02
Published: 15 June 2020
View article titled, Abstract PR02: Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status
Journal Articles

A phase I study of temsirolimus in combination with metformin in advanced solid tumors

Mary Jean Mackenzie, Eric Winquist, Scott Ernst, Craig Johnson, Paul O'Brien
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15_Supplement): B1.
Published: 15 August 2014
View article titled, A phase I study of temsirolimus in combination with metformin in advanced solid tumors
Journal Articles

Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

Fred Saad, Sebastien Hotte, Scott North, Bernie Eigl, Kim Chi, Piotr Czaykowski, Lori Wood, Michael Pollak, Scott Berry, Jean-Baptiste Lattouf, Som D. Mukherjee, Martin Gleave, Eric Winquist
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5765–5773.
https://doi.org/10.1158/1078-0432.CCR-11-0859
Published: 01 September 2011
View article titled, Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
Open the PDF for Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c in another window
Journal Articles

Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination

Carol A. Townsley, Gregory R. Pond, Amit M. Oza, Hal W. Hirte, Eric Winquist, Glenwood Goss, Pamela Degendorfer, Malcolm J. Moore, Lillian L. Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 2141–2149.
https://doi.org/10.1158/1078-0432.CCR-05-1798
Published: 11 April 2006
View article titled, Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination
Open the PDF for Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination in another window